Sanofi–GSK COVID-19 vaccine
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Other names | VAT00002, VAT00008 |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
Sanofi–GSK COVID-19 vaccine also known as VAT00002 and VAT00008[1] is a COVID-19 vaccine candidate developed by Sanofi Pasteur and GSK.[2][3][4]
Technology[edit]
VAT00008 is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine.[5][6]
Development[edit]
VAT00008 is under development by the French pharmaceutical and the British-American pharmaceutical company GlaxoSmithKline.[7] Advanced clinical trials of the vaccine were delayed in December 2020 after it failed to produce a strong immune response in people over the age of 50, most likely due to an insufficient antigen concentration in the vaccine, delaying the launch of the vaccine to late 2021.[8]
On 27 May 2021, the vaccine began a Phase III trial involving 35,000 participants.[9]
Deployment[edit]
In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi. It uses a recombinant protein-based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during the first half of 2021.[10] The company also agreed to a $2.1 billion deal with the United States to produce 100 million doses of the vaccine.[11]
References[edit]
- ^ "Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 28 May 2021.
- ^ Clinical trial number NCT04537208 for "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older" at ClinicalTrials.gov
- ^ Clinical trial number NCT04762680 for "Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)" at ClinicalTrials.gov
- ^ "Study of Recombinant Protein Vaccine with Adjuvant against COVID-19 in Adults 18 Years of Age and Older". pactr.samrc.ac.za. Pan African Clinical Trials Registry. Retrieved 24 March 2021.
- ^ "Sanofi, GSK announce positive results for Covid-19 vaccine candidate". STAT. 17 May 2021. Retrieved 18 May 2021.
- ^ "The Adjuvanted Recombinant Protein-based Vaccine Candidate". www.sanofi.com. Retrieved 18 May 2021.
- ^ "Coronavirus vaccine trial begun by drug firms GSK and Sanofi". BBC News. 3 September 2020. Retrieved 20 April 2021.
- ^ Taylor NP (11 December 2020). "Weak clinical data force Sanofi, GSK to delay COVID-19 vaccine". Fierce Biotech. Retrieved 25 January 2021.
- ^ Armitage, Jim (27 May 2021). "GlaxoSmithKline shareholders "relieved" as Elliott rules out aggressive demands". London Evening Standard.
- ^ "Coronavirus vaccine: UK signs deal with GSK and Sanofi". BBC News. 29 July 2020.
- ^ Lovelace Jr B. "U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine". CNBC.
External links[edit]
 |
Scholia has a profile for Sanofi–GSK COVID-19 vaccine (Q106265257). |
